Oral Wegovy Enters Workers' Comp: Pricing the GLP-1 Severity Shift

From tracking workers' compensation medical severity across NCCI filings for years, one pattern has been persistent: obesity complicates everything. It extends disability duration, inflates surgical complication rates, and compounds medical costs at every maturity. The question was always whether the WC system could intervene on obesity directly, or whether it would simply absorb the cost differential as a structural feature of the loss distribution. On December 22, 2025, the FDA answered part of that question by approving oral semaglutide (Wegovy) at the 25 mg daily dose for chronic weight management, creating the first pill-form GLP-1 receptor agonist available for obesity treatment. For workers' compensation pricing actuaries, this opens a new variable in medical severity trend selection that demands a structured framework.

The Obesity Cost Multiplier in Workers' Compensation

NCCI's research on obesity and workplace injuries established the baseline that pricing actuaries need to internalize before modeling GLP-1 effects. Medical costs for claims with an obesity comorbidity diagnosis grow to four times those of non-obese claims at 36 months of development. By 60 months, the differential exceeds five times. That is not a marginal difference; it is a structural divergence in the loss development pattern that concentrates in the tail.

The Journal of Occupational and Environmental Medicine provided a complementary data point from a study of approximately 2,300 injured workers in Louisiana. Average costs reached $470,000 for obese workers versus $180,000 for normal-weight workers, a 2.6x multiple on total claim cost. Overweight workers (below the obesity threshold) averaged $270,000, confirming a dose-response relationship between BMI and claim severity.

These cost differentials are not evenly distributed across the book. WCRI data and NCCI comorbidity research suggest that roughly 20% of lost-time workers' compensation claims carry an obesity comorbidity diagnosis. That 20% share, combined with the 4-5x cost multiplier, means obesity-comorbid claims consume a disproportionate share of aggregate medical severity, particularly in the later development periods where the cost curve diverges most sharply from non-obese claims.

Oral Wegovy: The Clinical Case

The OASIS 4 Phase 3 trial enrolled 307 adults with obesity or overweight (BMI of 30 or above, or 27 or above with at least one comorbidity) and randomized them to oral semaglutide 25 mg daily or placebo. The adherence-adjusted results showed 16.6% mean body weight loss at 64 weeks, compared with 2.7% for placebo. One-third of adherent participants achieved at least 20% weight loss. In the treatment-policy analysis covering all participants regardless of adherence, the weight loss was 13.6% versus 2.2%.

For workers' compensation, the critical clinical question is whether that weight loss translates into functional recovery gains: shorter disability duration, fewer surgical complications, and faster return to work. The evidence base here is promising but incomplete. Paradigm Corp has noted that obesity prolongs disability, increases surgical complication rates, and worsens musculoskeletal conditions, all of which are high-frequency WC injury categories. Weight reduction of 10-15% in a claimant with BMI 35 who suffered a lower back injury could meaningfully accelerate the return-to-work timeline and reduce the probability of chronic pain transition.

The previous barrier to GLP-1 uptake in WC was the injection requirement. Self-administered subcutaneous injections face compliance friction in WC populations where medication management is often complicated by injury-related limitations and variable clinical oversight. Oral semaglutide removes that barrier. However, the pill introduces its own compliance challenge: it must be taken on an empty stomach with no more than four ounces of plain water, at least 30 minutes before any food, beverages, or other oral medications. That dosing protocol adds friction that WC pharmacy benefit managers will need to monitor.

The Compensability Screen: Geographic Risk Segmentation

Before any GLP-1 cost enters a WC claim, it must pass a compensability determination. This is the first filter in the pricing framework, and it varies substantially by state.

The foundational question, as Preferred Medical framed it in early 2026, is whether obesity is "directly tied to the work injury, such as significant weight gain following prolonged post-injury immobility" or is a pre-existing condition the claim should not bear. Most state WC statutes apply some version of the "take the worker as you find them" doctrine, meaning employers accept employees with their existing health conditions. But the treatment of a pre-existing condition is only compensable to the extent it is aggravated by or causally connected to the work injury.

In practice, this produces three tiers of compensability exposure:

High compensability states: Jurisdictions with broad aggravation doctrines and liberal medical treatment standards, where a treating physician's recommendation that weight loss will promote recovery from the compensable injury may be sufficient to authorize GLP-1 treatment. Courts in several states have found weight loss surgery compensable when recommended to resolve work-related back and lower-extremity injuries.

Moderate compensability states: States requiring a documented causal nexus between the work injury and the weight gain (for example, a claimant who gained 40 pounds during 18 months of post-surgical immobility following a compensable knee injury). The temporal and causal link must be established in the medical record.

Low compensability states: Jurisdictions with strict pre-existing condition carve-outs or narrow compensability standards that would exclude obesity treatment unless the obesity itself resulted directly from the work injury. North Carolina's Supreme Court, for instance, has limited compensability to cases where the workplace injury "directly caused" or "materially accelerated" the condition requiring treatment.

For pricing purposes, this geographic variation creates a compensability pass-through rate that varies by state. A pricing actuary building a countrywide medical severity trend must weight this rate by the state distribution of the book, recognizing that the same clinical scenario produces different cost outcomes depending on jurisdiction.

The Pricing Mechanism: Two-Component Severity Adjustment

The standard NCCI medical severity trend selection method uses an exponential least-squares fit to countrywide medical-only and lost-time severity data over the most recent experience period. Layering GLP-1 authorization into this framework requires a two-component adjustment that captures both the cost and the benefit of treatment.

Component 1: Pharmacy Cost Loading. The expected per-claim GLP-1 cost is the product of the monthly prescription cost, the average treatment duration, the compensability pass-through rate, and the real-world adherence rate. At the current list price of $1,349 per month (with Novo Nordisk's announced reduction to approximately $675 effective January 2027), a 12-month treatment course costs $16,188 at 2026 pricing. Adjust this for the compensability screen pass-through rate, which we estimate at 15-30% depending on state mix, and for real-world adherence below 50% at 12 months. The effective per-claim pharmacy loading for the obesity-comorbid subset becomes:

Pharmacy Loading = Monthly Cost × Treatment Months × Pass-Through Rate × Adherence Rate × Obesity Comorbidity Share

Using midpoint assumptions ($1,349/month, 10 months effective duration adjusted for discontinuation, 22% pass-through, 45% adherence, 20% obesity share), the per-claim pharmacy loading across the full book runs approximately $270 per lost-time claim. That is a modest addition to an average medical severity base that NCCI pegs at roughly $30,000 for lost-time claims, representing less than 1% of the total.

Component 2: Severity Compression Credit. This is where the economics potentially flip. NCCI's obesity cost differentials show that obese claims generate four to five times the medical costs of non-obese claims at 36-60 months. If effective GLP-1 treatment shifts even a fraction of obese claims toward the non-obese severity curve, the savings at later development maturities are substantial.

Consider a simplified example. An obese lost-time claim that would develop to $150,000 in ultimate medical cost (versus $37,500 for a comparable non-obese claim) represents $112,500 in excess severity attributable to the obesity comorbidity. If GLP-1 treatment achieves a 30% compression of that differential for the subset of claims where the medication is both authorized and effective (pass-through rate times adherence rate times clinical response rate), the per-claim severity credit for the obesity-comorbid subset is approximately $112,500 × 30% × 22% × 45% = $3,341. Applied to the 20% obesity share of the book, the credit per average lost-time claim is roughly $668.

The net severity trend adjustment is the sum of the two components: approximately +$270 in pharmacy loading and -$668 in severity compression, yielding a net favorable impact of roughly -$398 per lost-time claim, or approximately -1.3% on the medical severity base.

Sensitivity Analysis: The Break-Even Adherence Rate

The net impact is highly sensitive to three parameters: the pass-through rate, the adherence rate, and the severity compression factor. The pricing actuary should run the model across a range of assumptions and identify the break-even point at which the pharmacy loading exactly offsets the severity credit.

Holding the pass-through rate at 22% and the severity compression factor at 30%, the break-even adherence rate is approximately 18%. Below that level, so few claimants remain on therapy long enough to generate meaningful weight loss that the pharmacy spend exceeds the medical savings. At the observed real-world adherence rate of 40-45%, the model produces a net favorable impact, but the margin is narrow enough that a shift in any input assumption can flip the sign.

The pass-through rate is the parameter with the widest confidence interval. In states with broad compensability standards and aggressive treating physicians, pass-through could reach 40% or higher, amplifying both the cost and the credit. In restrictive states, it may be below 10%, rendering the entire adjustment immaterial. This interstate variation mirrors the 25-fold gap in WC Rx costs that WCRI documented across 31 states, where regulatory environment determines how much of a new treatment modality enters the paid claim stream.

Pricing actuaries should also consider the time lag. GLP-1 treatment effects on weight and functional recovery take 6-12 months to materialize, meaning the severity compression credit does not appear in the same calendar year as the pharmacy loading. Loss cost filings covering a 12-month rate effective period may capture the front-loaded pharmacy cost without the trailing severity credit, creating a timing mismatch that overstates the net cost in the short run.

Loss Development Factor Implications

The obesity cost differential is not uniform across development periods. NCCI's data shows the divergence widening over time: 4x at 36 months, 5x-plus at 60 months. This pattern means obesity-driven severity is concentrated in the tail of the loss development triangle, exactly where IBNR estimates carry the most uncertainty.

If GLP-1 treatment compresses the obesity severity curve, the tail of the development pattern shortens. Claims that would have continued generating medical costs through 48-72 months instead settle closer to the non-obese pattern, with development largely complete by 36 months. The actuarial implication is a reduction in loss development factors at later maturities.

For a pricing actuary selecting LDFs for a loss cost filing, this creates a monitoring requirement. If GLP-1 utilization becomes material in the claim population (which requires the pass-through and adherence hurdles described above), the historical development pattern overstates future development for the treated subset. The adjustment is to segment the triangle into obesity-comorbid and non-obesity-comorbid components, apply reduced LDFs to the treated subset based on expected severity compression, and blend back to a single development pattern weighted by mix.

This segmentation is not yet practical with most carriers' data infrastructure, which makes it a forward-looking consideration rather than an immediate filing adjustment. But the spillover from employer health plan GLP-1 coverage, where 67% of large employers now cover GLP-1s for weight management according to the Business Group on Health's 2026 survey, will increase the baseline health of the insured workforce over time. Workers entering the WC system with lower BMIs due to group health plan GLP-1 access may generate lower severity from the outset, independent of any WC-specific GLP-1 authorization.

Utilization Management as a Pricing Lever

The pass-through rate is not exogenous; it is directly shaped by utilization management protocols. Preferred Medical's 2026 framework for oral GLP-1s in workers' compensation outlined four gatekeeping criteria: alignment with FDA-approved indications, documented BMI thresholds (30 or above, or 27 or above with qualifying comorbidity), medical necessity tied to functional recovery goals, and measurable progress monitoring.

Carriers and TPAs that enforce these protocols will have lower pass-through rates, higher average treatment appropriateness, and consequently better net severity outcomes per GLP-1 dollar spent. Carriers with lax utilization management risk authorizing GLP-1 treatment for claims where the obesity is genuinely pre-existing and unrelated to the work injury, adding pharmacy cost without a corresponding severity credit.

For pricing actuaries building the medical severity trend assumption, the utilization management posture of the carrier or state program is an assumption that should be explicitly documented. A trend selected for a well-managed book will differ from one selected for a book with minimal GLP-1 gatekeeping.

Why This Matters for Loss Cost Filings

The GLP-1 compensability channel is still early. Oral Wegovy became available in pharmacies in January 2026, and the first WC authorizations are likely still working through clinical review in most jurisdictions. The paid claim data will not show a material GLP-1 signal for another 12-18 months. But the pricing framework needs to be built now, because loss cost filings use prospective trend assumptions that extend through the rate effective period.

NCCI's April 2026 Medical Inflation Insights showed medicinal drug prices declining 0.2% year over year, but overall medical severity running at 4% in 2025, outpacing the Workers Compensation Weighted Medical Price Index. The GLP-1 pharmacy loading adds a new cost component that the WCWMI does not capture, while the severity compression credit operates on a different timeline and affects different development periods than traditional medical trend factors.

Pricing actuaries preparing 2026 and 2027 WC loss cost indications should consider three steps. First, estimate the obesity comorbidity share of the book using diagnosis codes and flag it as a subpopulation for sensitivity testing. Second, build the two-component model outlined above with carrier-specific assumptions for pass-through rate (informed by state mix and UM protocols) and adherence rate (informed by pharmacy benefit manager data). Third, document the GLP-1 adjustment as a separate line item in the trend selection, with explicit sensitivity ranges, so that regulators and peer reviewers can evaluate the assumption independently.

The net effect may be small in the near term. But obesity is a structural driver of WC medical severity, and GLP-1 medications represent the first pharmacological intervention that could meaningfully alter the cost trajectory for the 20% of claims where it matters most. Getting the pricing framework right before the data arrives is the actuarial discipline that prevents both over-reaction and under-reaction when the first loss development triangles with GLP-1 exposure start to emerge.